)
Accendra Health (ACH) investor relations material
Accendra Health Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
CEO Ed Pesicka announced plans to retire by the end of 2026, with succession planning underway following significant transformation, including the sale of the P&HS segment and balance sheet optimization.
The company completed the sale of the Products & Healthcare Services (P&HS) business for $375 million, retaining a 5% equity interest, and now operates as a single segment.
Q2 and first half of 2026 focused on continuing operations after the P&HS divestiture, with ongoing transition from a large commercial payor and nationwide rollout of growth initiatives.
The company positions itself as a nationwide leader in patient direct healthcare, with a diversified payor and product portfolio.
Major debt reduction and balance sheet optimization were achieved, resetting the debt maturity profile and improving liquidity.
Financial highlights
Q2 2026 net revenue was $613.2 million, down from $681.9 million in Q2 2025, primarily due to the termination of major commercial payor contracts.
Adjusted EBITDA for Q2 2026 was $60.1 million, down from $96.6 million in Q2 2025, with a slight margin improvement from Q1.
Free cash flow for Q2 2026 was $(25.1) million, compared to $15.2 million in Q2 2025.
GAAP loss from continuing operations was $(89.1) million in Q2 2026 versus $(83.8) million in Q2 2025.
Cash and cash equivalents at June 30, 2026, were $7.7 million, down from $282 million at year-end 2025.
Outlook and guidance
Full-year 2026 revenue guidance is $2.45–$2.55 billion, with adjusted EBITDA expected at $300–$320 million.
Free cash flow for 2026 is projected to be breakeven to slightly positive, with stronger performance anticipated in Q4 to set up 2027.
Interest expense for 2026 is expected at $142–$146 million; cash interest $158–$162 million.
Management expects up to $65 million in additional exit and realignment costs related to the P&HS sale.
Guidance is based on assumptions about market conditions, demand, supply chain, and interest rates.
- Plans to raise up to $200 million via a flexible shelf offering for general corporate purposes.ACH
Registration filing - All proposals passed as the company advances its home-based care strategy nationwide.ACH
AGM 2026 - Q1 2026 revenue fell 6.8% to $627.8M, with a $1.5B balance sheet reset to boost liquidity.ACH
Q1 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ACH
Proxy filing - Shareholders to vote on directors, auditor, executive pay, and expanded equity plan amid strategic transformation.ACH
Proxy filing - 2026 guidance projects $2.55–$2.65B revenue, $335–$355M EBITDA, and strong cash flow.ACH
Q4 2025 - Q3 revenue up 5% to $2.7B, driven by Patient Direct and $198M debt reduction.ACH
Q3 2024 - Q2 revenue up 4–4.2% to $2.67–$2.7B; Rotech deal announced; 2024 outlook reaffirmed.ACH
Q2 2024 - $1.36B Rotech deal expands Patient Direct, targets $5B revenue, $50M synergies by year three.ACH
M&A Announcement
Next Accendra Health earnings date
Next Accendra Health earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage